Vascular endothelial growth factor & basic fibroblast growth factor polymorphism as prognostic factors in Non-Hodgkin Lymphoma


Lymphoma growth and progression may be enhanced by angiogenesis. Both vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF) play an important role in this process. The
present study aimed to investigate the association of VEGF -936C/T and bFGF -921C/G gene polymorphisms
with the clinicopathological characteristics of the studied patients and progression of NHL disease.
Patients and methods: Clinico-hematological profiles were done for 50 NHL patients. The genotypes and
allelic frequencies of VEGF and bFGF polymorphisms were detected using Polymerase Chain ReactionRestriction Fragment Length Polymorphism (PCR-RFLP). PCR products after adding restriction endonuclease
were analyzed using QIAxcel advanced (automated) instrument.
Results: there was a trend of significance of VEGF 936-T allele among NHL patients with advanced clinical
staging compared to patients with early stages with
P value 0.082. As regards the progression of the disease
determined by international prognostic index (IPI), it was noticed that there was a borderline significance
between VEGF CT genotype and IPI score among patients with intermediate high/high IPI compared to
patients with low/intermediate low IPI with
P value 0.074. The bFGF 921-G variant was associated frequently
with aggressive histological subtype of NHL and showed a borderline significance with NHL patients
presented with intermediate high/high IPI score and BM infiltration with
P value 0.098 and 0.054 respectively.
Conclusion: our results demonstrated that VEGF-936C/T and bFGF-921C/G gene polymorphisms may
potentially affect the progression of NHL. Further larger scale studies are needed.